Name
OÜ Chemedest
Registry code
10784296
VAT number
EE100784776
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
06.07.2001 (23)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-8 622 €
-
-
2 112 €
0
Submitted
No tax arrears
-408%
-2%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Silje Seli 19.08.1988 (36) | 100% - 2 556.00 EUR | Board member | Direct ownership | |
| Neinar Seli 07.12.1959 (64) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member |
| 2019 17.06.2020 | 2020 16.06.2021 | 2021 16.06.2022 | 2022 20.06.2023 | 2023 17.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - |
| Net profit (loss) for the period | 33 578 € | -8 555 € | -8 354 € | -8 492 € | -8 622 € |
| Profit Margin | - | - | - | - | - |
| Current Assets | 455 679 € | 449 680 € | 441 326 € | 432 834 € | 462 789 € |
| Fixed Assets | 2 556 € | 0 € | - | - | - |
| Total Assets | 458 235 € | 449 680 € | 441 326 € | 432 834 € | 462 789 € |
| Current Liabilities | 2 100 € | 2 100 € | 2 100 € | 2 100 € | 10 677 € |
| Non Current Liabilities | 420 000 € | 420 000 € | 420 000 € | 420 000 € | 450 000 € |
| Total Liabilities | 422 100 € | 422 100 € | 422 100 € | 422 100 € | 460 677 € |
| Share Capital | - | - | - | - | - |
| Equity | 36 135 € | 27 580 € | 19 226 € | 10 734 € | 2 112 € |
| Employees | 0 | 0 | 0 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | - | - | - | - |
| 2023 Q4 | - | - | - | - |
| 2023 Q3 | - | - | - | - |
| 2023 Q2 | - | - | - | - |
| 2023 Q1 | - | - | - | - |
| 2022 Q4 | - | - | - | - |
| 2022 Q3 | - | - | - | - |
| 2022 Q2 | - | - | - | - |
| 2022 Q1 | - | - | - | - |
| 2021 Q4 | - | - | - | - |
| 2021 Q3 | - | - | - | - |
| 2021 Q2 | - | - | - | - |
| 2021 Q1 | - | - | - | - |
| 2020 Q4 | - | - | - | - |
| 2020 Q3 | - | - | - | - |
| 2020 Q2 | - | - | - | - |
| 2020 Q1 | - | - | - | - |
